Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to -$80,000.

  • Niagen Bioscience's Gains from Investment Securities rose 28.57% to -$15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$59,000, marking a year-over-year increase of 23.38%. This contributed to the annual value of -$80,000 for FY2024, which is 6.67% down from last year.
  • According to the latest figures from FY2024, Niagen Bioscience's Gains from Investment Securities is -$80,000, which was down 6.67% from -$75,000 recorded in FY2023.
  • Niagen Bioscience's 5-year Gains from Investment Securities high stood at $272,000 for FY2020, and its period low was -$108,000 during FY2021.
  • Its 3-year average for Gains from Investment Securities is -$74,000, with a median of -$75,000 in 2023.
  • Per our database at Business Quant, Niagen Bioscience's Gains from Investment Securities plummeted by 139.71% in 2021 and then skyrocketed by 37.96% in 2022.
  • Yearly analysis of 5 years shows Niagen Bioscience's Gains from Investment Securities stood at $272,000 in 2020, then crashed by 139.71% to -$108,000 in 2021, then surged by 37.96% to -$67,000 in 2022, then declined by 11.94% to -$75,000 in 2023, then dropped by 6.67% to -$80,000 in 2024.